Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end?
In a report released today, Geoff Meacham from Citi maintained a Buy rating on BioNTech SE. The company’s shares opened today at $101.91.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...
TD Cowen analyst Yaron Werber maintained a Hold rating on BioNTech SE today and set a price target of $120.00. The company’s shares closed yesterday at $102.21.Elevate Your Investing Strategy: Take advantage...
In a report released on September 30, Evan Seigerman from BMO Capital assigned a Buy rating to BioNTech SE, with a price target of $143.00. The company’s shares closed yesterday at $102.21.Elevate Your...
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END
MarketNewsUpdates News Commentary
/CNW/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant...
September S&P 500 E-Mini futures (ESU25) are up +0.19%, and September Nasdaq 100 E-Mini futures (NQU25) are up +0.08% this morning, pointing to a slightly higher open on Wall Street amid optimism ahead...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The FDA's unprecedented accelerated approval pace through August 2025 has delivered breakthrough treatments...
Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing...